AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03404193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03404193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03404193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02315742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Move Program
Description: Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
Study NCT03626103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Brief ED Intervention (BI)
Description: Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
Study NCT03626103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Text
Description: Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
Study NCT02833233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Study NCT02293031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene-activated matrix Nucleostim
Description: Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®.
Study NCT05203354 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband Ultraviolet B
Description: patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
Study NCT05203354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
Study NCT00454766 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
Study NCT00645541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping
Description: Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
Study NCT05632445 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban vs. DAPT
Description: Apixaban vs DAPT after LAAO
Study NCT02019043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Syphilis testing with routine HIV bloodwork
Description: The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
Study NCT03446729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
Study NCT03446729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
Study NCT02811185 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]-Fludeoxyglucose
Description: Radiopharmaceutical imaging agent
Study NCT05695625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia + bilateral erector spine plane block
Description: Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered.
Study NCT05695625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value >4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values >4, 1000mg paracetamol intravenously was administered.
Study NCT03711851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and commitment therapy (Web-based)
Description: 9 week program with minimal contact with therapist (predominantly self-help)
Study NCT03711851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and commitment therapy (bibliotherapy)
Description: 9 week program with contact with therapist (predominantly self-help)
Study NCT03711851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help Education pamphlets on pain (active control group)
Description: 9 week program with contact with therapist (predominantly self-help)
Study NCT02736305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Once a day for 21 days in a 28 days cycle
Study NCT02261051 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
Study NCT01203748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + Lines ablation
Description: Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
Study NCT01203748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Pulmonary vein antrum isolation
Study NCT01203748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + CFE ablation
Description: Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
Study NCT01054846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle helmet from Bell Sports Inc.
Description: As described under the respective arm
Study NCT01054846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicycle helmet education only
Description: As described under the respective arm
Study NCT02325167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBT
Description: participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
Study NCT02325167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment-as-usual
Description: participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
Study NCT02169453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: OPC, Opicapone
Study NCT02169453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PLC, Placebo
Study NCT02169453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® CR 100/25
Description: Controlled-release levodopa/carbidopa 100/25 mg
Study NCT04143074 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multidisciplinary behavioral intervention
Description: behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
Study NCT00562133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: 100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
Study NCT00562133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: 100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
Study NCT02982915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered
Study NCT02982915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose Vaccine
Description: Intramuscular injection
Study NCT04473430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)
Description: Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance. The sensor uses a novel semi-permeable membrane that blocks interference with most clinically relevant substances, including high levels of urea and creatinine, and commonly used medications. Dexcom G6 CGM is a commercially-available, minimally invasive sensor, with a flexible and thin wire that is inserted into the abdominal subcutaneous tissue. Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).
Study NCT04473430 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG
Description: POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.
Study NCT00001984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and DSG
Description: Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
Study NCT02966951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal stem cell
Description: Intra-articular adipose tissue derived mesenchymal stem cell injection.
Study NCT05748054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride
Description: A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
Study NCT02802098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
Study NCT02802098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Study NCT02271425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib Tablet
Description: Oral administration
Study NCT02271425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib Intravenous
Description: Intravenous administration
Study NCT01190137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) or ergocalciferol (D2)
Description: 400 IU administered as 1 drop daily for 3 months
Study NCT01190137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (D3) or ergocalciferol (D2)
Description: 400 IU administered as 1 drop daily for 3 months
Study NCT04094025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dATS
Description: d-Amphetamine Transdermal System
Study NCT02464033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum
Description: Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
Study NCT02464033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT02464033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT05225350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months.
Study NCT03218241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRT064445
Description: Intravenous
Study NCT03218241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous to mimic PRT064445
Study NCT00597441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymic Transplantation for Recipients of UCB transplant
Description: Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
Study NCT00028743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
Study NCT00028743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
Study NCT00028743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
Study NCT00028743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: 4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.2U/Kg
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.1U/Kg
Description: Single dose of 0.1U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone insulin lispro 0.4U/Kg
Description: Single dose of 0.4U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study NCT02146651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Study NCT06236282 — intervention group
Intervention type: DEVICE
Intervention: ArtiSential®
Description: Articulated laparoscopic device made by Livsmed Co, South Korea.
Study NCT05863858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID
Description: The eradication rate of H. Pylori with levofloxacin-based sequential therapy
Study NCT05863858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID
Description: The eradication rate of H. Pylori with moxifloxacin-based triple therapy
Study NCT01520493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal exercises
Description: Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
Study NCT02540057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexor carpi radialis
Description: Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
Study NCT02540057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abductor pollicis longus
Description: Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
Study NCT03885830 — intervention group
Intervention type: DRUG
Intervention: Bosutinib
Description: Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
Study NCT03885830 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Description: Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
Study NCT03885830 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
Study NCT03885830 — intervention group
Intervention type: DRUG
Intervention: Nilotinib
Description: Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
Study NCT03275753 — intervention group
Intervention type: OTHER
Intervention: Visual Function Tests
Description: All subjects will undergo a battery of visual function tests
Study NCT02949505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home prehabilitation program
Description: 12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
Study NCT03589092 — intervention group
Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS Panel, Whole exome/genome sequencing
Study NCT02757859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
Study NCT02757859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavage
Description: Receive EIPL-S